- Home
- APGE vs RLAY Comparison
APGE vs RLAY Comparison
Compare APGE & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | APGE | RLAY |
|---|---|---|
| Founded | 2022 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 3.8B |
| IPO Year | 2023 | 2020 |
Fundamental Metrics
Financial Performance| Metric | APGE | RLAY |
|---|---|---|
| Price | $132.75 | $18.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 10 |
| Target Price | ★ $109.67 | $19.50 |
| AVG Volume (30 Days) | ★ 4.9M | 4.5M |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.78 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $15,355,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $324.03 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 53.44 |
| 52 Week Low | $34.34 | $3.03 |
| 52 Week High | $133.16 | $19.93 |
Technical Indicators
Market Signals| Indicator | APGE | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 81.33 | 63.66 |
| Support Level | $73.70 | $6.67 |
| Resistance Level | $133.16 | N/A |
| Average True Range (ATR) | 2.11 | 0.99 |
| MACD | 3.45 | 0.28 |
| Stochastic Oscillator | 99.20 | 72.13 |
Price Performance
Historical ComparisonAbout APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.